293 related articles for article (PubMed ID: 33076544)
1. Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities.
Hamamichi S; Fukuhara T; Hattori N
Toxins (Basel); 2020 Oct; 12(10):. PubMed ID: 33076544
[TBL] [Abstract][Full Text] [Related]
2. Antibody internalization after cell surface antigen binding is critical for immunotoxin development.
Kuo SR; Alfano RW; Frankel AE; Liu JS
Bioconjug Chem; 2009 Oct; 20(10):1975-82. PubMed ID: 19785403
[TBL] [Abstract][Full Text] [Related]
3. Immunotoxin FN18-CRM9 induces stronger T cell signaling than unconjugated monoclonal antibody FN18.
Hamawy MM; Tsuchida M; Cho CS; Manthei ER; Fechner JH; Knechtle SJ
Transplantation; 2001 Aug; 72(3):496-503. PubMed ID: 11502982
[TBL] [Abstract][Full Text] [Related]
4. Antibody internalization studied using a novel IgG binding toxin fusion.
Mazor Y; Barnea I; Keydar I; Benhar I
J Immunol Methods; 2007 Apr; 321(1-2):41-59. PubMed ID: 17336321
[TBL] [Abstract][Full Text] [Related]
5.
Mousavi A; Sabouri A; Hassanzadeh Eskafi A; Alirahimi E; Kazemi-Lomedasht F; Ghaderi H; Behdani M
Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):113-117. PubMed ID: 34076502
[TBL] [Abstract][Full Text] [Related]
6. Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity.
Reiter Y; Di Carlo A; Fugger L; Engberg J; Pastan I
Proc Natl Acad Sci U S A; 1997 Apr; 94(9):4631-6. PubMed ID: 9114042
[TBL] [Abstract][Full Text] [Related]
7. Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.
Antignani A; Mathews Griner L; Guha R; Simon N; Pasetto M; Keller J; Huang M; Angelus E; Pastan I; Ferrer M; FitzGerald DJ; Thomas CJ
PLoS One; 2016; 11(8):e0161415. PubMed ID: 27556570
[TBL] [Abstract][Full Text] [Related]
8. Whatever happened to immunotoxins? Research, and hope, are still alive.
Holzman DC
J Natl Cancer Inst; 2009 May; 101(9):624-5. PubMed ID: 19401548
[No Abstract] [Full Text] [Related]
9. Fusogenics: a recombinant immunotoxin-based screening platform to select internalizing tumor-specific antibody fragments.
Cizeau J; Torres MG; Cowling SG; Stibbard S; Premsukh A; Entwistle J; MacDonald GC
J Biomol Screen; 2011 Jan; 16(1):90-100. PubMed ID: 21131595
[TBL] [Abstract][Full Text] [Related]
10. Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment.
Matar AJ; Pathiraja V; Wang Z; Duran-Struuck R; Gusha A; Crepeau R; Tasaki M; Sachs DH; Huang CA
Transpl Immunol; 2012 Aug; 27(1):52-4. PubMed ID: 22676970
[TBL] [Abstract][Full Text] [Related]
11. Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines - Construction and characterization.
Potala S; Verma RS
J Biotechnol; 2010 Jul; 148(2-3):147-55. PubMed ID: 20580754
[TBL] [Abstract][Full Text] [Related]
12. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.
Pirie CM; Hackel BJ; Rosenblum MG; Wittrup KD
J Biol Chem; 2011 Feb; 286(6):4165-72. PubMed ID: 21138845
[TBL] [Abstract][Full Text] [Related]
13. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].
Chiron MF
Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366
[TBL] [Abstract][Full Text] [Related]
14. High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody libraries.
Hou SC; Chen HS; Lin HW; Chao WT; Chen YS; Fu CY; Yu CM; Huang KF; Wang AH; Yang AS
Sci Rep; 2016 Aug; 6():31878. PubMed ID: 27550798
[TBL] [Abstract][Full Text] [Related]
15. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity.
Greenfield L; Johnson VG; Youle RJ
Science; 1987 Oct; 238(4826):536-9. PubMed ID: 3498987
[TBL] [Abstract][Full Text] [Related]
16. Promising fusion protein design to target the U87 MG glioma cell line.
Jing C; Yuan L; Xingguo P; Zhijie H; Zai-xi C; Ru Z; Jian Y
Asian Pac J Cancer Prev; 2011; 12(4):935-7. PubMed ID: 21790229
[TBL] [Abstract][Full Text] [Related]
17. Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications.
Wu T; Zhu J
Int Immunopharmacol; 2021 Jul; 96():107759. PubMed ID: 34162138
[TBL] [Abstract][Full Text] [Related]
18. Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH.
Liu X; Tan Q; Wen J; Wang X; Yang G; Li Y; Lu M; Ye W; Si A; Ma S; Ding T; Sun L; Liu F; Zhang M; Jiang T; Gao W
J Transl Med; 2023 Aug; 21(1):572. PubMed ID: 37626430
[TBL] [Abstract][Full Text] [Related]
19. A new class of antigen-specific killer cells.
Yang AG; Chen SY
Nat Biotechnol; 1997 Jan; 15(1):46-51. PubMed ID: 9035105
[TBL] [Abstract][Full Text] [Related]
20. Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells.
Hellmann I; Waldmeier L; Bannwarth-Escher MC; Maslova K; Wolter FI; Grawunder U; Beerli RR
Front Immunol; 2018; 9():2490. PubMed ID: 30450096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
